Søgning
Søgning på udtrykket 'clostri' giver 25 resultater
Dokumenter [3] Nyt fra tidsskrifterne [+20] Aktuelle smitsomme sygdomme [2]
Dokumenter [3]
National klinisk guideline, Dansk Selskab for Gastroenterologi og Hepatologi (DSGH), Dansk Selskab for Klinisk Immunologi (DSKI), Dansk Selskab for Klinisk Mikrobiologi (DSKM) og Dansk Selskab for Infektionsmedicin (DSI)
Nyt fra tidsskrifterne [+20]
Der er mere end 20 resultater, måske du vil se flere resultater her?
Nature
2.01.2025
Clinical Microbiology and Infection
9.12.2024
To study the presence of Clostridioides difficile in faeces of patients with recurrent C. difficile infection (rCDI) before and after faecal microbiota transplantation (FMT) and to identify risk factors for faecal C. difficile and CDI recurrence.
International Journal of Infectious Diseases
7.12.2024
Clostridium species are spore-forming, gram-positive bacilli widely distributed in nature, including soil, and intestinal tracts of humans and animals [1,2]. To date, approximately 200 Clostridium spp. have been identified. Clostridium spp. cause enteritis, skin and soft tissue infections, peritonitis, and bacteremia [1,2]. In particular, the incidence of bacteremia caused by Clostridium spp. is high among older adults with comorbidities [3,4]. Clostridium spp. account for 10–25% of obligate anaerobic bac…
Proceedings of the National Academy of Sciences: Immunology and Inflammation
2.12.2024
Proceedings of the National Academy of Sciences, Volume 121, Issue 45, November 2024.
International Journal of Infectious Diseases
26.11.2024
… C. difficile, specifically in fulminant disease where outcomes are poor [1,2]. About 17% of patients with Clostridioides difficile infection (CDI) experience relapse within 2-8 weeks; in severe or fulminant cases, 20% require colectomy and up to 35% will die [3,4]. Tigecycline (TGC) is a tetracycline-derivative antibiotic that has been recommended as an adjunct therapy in fulminant CDI if patients lack response to SOC antibiotics, but there are limited data exploring patient outcomes in this setting [5,6].
Trends in Microbiology
19.10.2024
Clostridium perfringens is a Gram-positive, anaerobic, rod-shaped bacterium that causes various diseases in humans and animals, resulting in significant economic losses worldwide. This bacterium forms heat- and chemical-resistant metabolically dormant spores which can survive in a wide range of environments, including soil, sediment, sewage, food, and the intestinal tracts of humans and animals. In favorable conditions, C. perfringens spores undergo biophysical changes, called germination, and form vegetati…
Infection
9.10.2024
. Abstract. Gas gangrene is a rare presentation of a necrotizing fasciitis, caused by Clostridium perfringens, C. septicum and other clostridial species. With its rapid progression it is a potentially life-threatening infection, that poses as a challenge in the clinical management requiring an interdisciplinary approach. . Here we present a 62-year-old woman, who developed neutropenic fever while undergoing chemotherapy for triple negative breast cancer…
Science
4.10.2024
Science, Volume 386, Issue 6717, Page 69-75, October 2024.
Clinical Microbiology and Infection
27.09.2024
The main international guidelines for the management of Clostridioides difficile (C. difficile) infection (CDI) diverge on the suggested treatment of its fulminant form [1-4]. As some authors pointed out [5], the therapeutic choices that are proposed by current guidelines [1-4] were based on few retrospective observational studies with several biases (Table 1).
Journal of Infectious Diseases
25.09.2024
Abstract . Clostridioides difficile infection (CDI) is a major cause of healthcare- and antibiotic-associated diarrhea. While fecal microbiota transplantation (FMT) shows promise for recurrent CDI, its mechanisms and long-term safety are not fully understood. Live biotherapeutic products (LBPs) using pre-defined bacterial consortia offer an alternative option, but the rational designing LBPs remains challenging. Here, we employ a computational pipeline and three metagenomic datasets to identify microbial st…
BMC Infectious Diseases
18.09.2024
. Abstract. . Background. The nosocomial transmission of toxin-producing Clostridioides difficile is a significant concern in infection control. C. difficile, which resides in human intestines, poses a risk of transmission, especially when patients are in close contact with medical staff. . . . Methods. To investigate the nosocomial transmis…
Clinical Infectious Diseases
13.09.2024
Fecal microbiota transplantationClostridioides difficile infectionrandomized controlled trial
Clinical Infectious Diseases
1.09.2024
Abstract . Clostridioides difficile (C. difficile) is a spore-forming, toxin-producing, anaerobic bacterium infecting the human gastrointestinal tract, causing diarrhea and life-threatening colitis. C. difficile epidemiology continues to evolve, and it is recognized as a major community-associated pathogen in addition to its established role in causing healthcare-associated infection. While current surveillance and prevention measures mainly focus on healthcare-associated C. difficile infections, much less …
Clinical Microbiology and Infection
29.08.2024
Clostridioides difficile (C. difficile) remains the leading cause of healthcare-associated diarrhoea, posing treatment challenges due to antibiotic resistance and high relapse rates. Fecal microbiota transplantation (FMT) is a novel treatment strategy to prevent relapses of C. difficile infection (CDI), however the exact components conferring colonisation resistance are unknown, hampering its translation to a medicinal product. Development of novel products independent of antibiotics, which increase colonis…
Clinical Infectious Diseases
24.08.2024
Journal of Infectious Diseases
24.08.2024
Abstract . Background . Microbiota-based treatments are effective in preventing recurrent Clostridioides difficile infection (rCDI). Fecal microbiota, live-jslm (REBYOTA®; RBL, previously RBX2660) was shown to prevent rCDI in a phase 3, randomized, double-blinded placebo controlled clinical trial (PUNCH™ CD3).Methods . Stool samples from participants in PUNCH™ CD3 who received a single blinded dose of rectally administered RBL or placebo were sequenced to determine microbial community composition and c…
Antimicrobial Agents And Chemotherapy
22.08.2024
Antimicrobial Agents and Chemotherapy, Ahead of Print.
Journal of Infectious Diseases
10.08.2024
Abstract . Background . Clostridioides difficile is a major cause of nosocomial post-antibiotic infections, often resulting in severe inflammation and watery diarrhea. Previous studies have highlighted the role of C. difficile flagellin FliC in activating the TLR5 receptor and triggering NF-κB cell signaling, leading to the release of pro-inflammatory cytokines. However, the microRNAs (miRNAs) mediated regulatory mechanisms underlying the FliC-induced inflammatory response remain unclear.Methods . miRNA ex…
Clinical Microbiology and Infection
8.08.2024
The objective of this study is to examine the comparative effectiveness of vancomycin and metronidazole in a confirmatory analysis of event-free survival (EFS) following initial infection in patients with Clostridioides difficile (C. difficile) from a German multicentre cohort study.
BMC Infectious Diseases
30.07.2024
. Abstract. . Background. Clostridioides difficile infection is associated with antibiotic use and manifests as diarrhea; however, emerging cases of fulminant diarrhea caused by binary toxin-producing C. difficile unrelated to prior antibiotic exposure have been reported. Although fulminant colitis caused by C. difficile has been documented, instances of intussusception remain scarce. Here, we present a case of adult intussu…
Aktuelle smitsomme sygdomme [2]
Aktuelle smitsomme sygdomme [2]
Eurosurveillance latest updates
11.01.2025
. Background. Clostridioides difficile infection (CDI) is a severe infection that needs to be monitored. This infection predominantly occurs in hospitalised patients after antimicrobial treatment, with high mortality in elderly patients. . . Aim. We aimed at estimating the incidence of CDI in Italian hospitals over 4 months in 2022. . . Methods. We estimated incidences of hospital-acquired CDI (HA-CDI), community or unknown CDI (CA/UA-CDI), recurrent CDI and overall CDI in 25 Italian hospitals, char…
Eurosurveillance latest updates
9.02.2024
. Background. Community-associated Clostridioides difficile infections (CA-CDI) have increased worldwide. Patients with CDI-related symptoms occurring